RxDoctor Payments Data

Joseph Brown, MD

Internal Medicine · Monticello, KYNPI 1619295540

Payments from drug & device makers

$1,996in general payments, 2019–2025

Across 131 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$359
  • AbbVie$332
  • Novo Nordisk$199
  • GSK$195
  • AstraZeneca$126
  • Merck$84
  • plus $700 from 21 others

What the payments were for

  • Food & beverage$1,98199%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,996 in reported general payments places this provider in the 75th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$3,243
Medicare patients
99
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$154,824
TrulicityDulaglutide122$139,180
JardianceEmpagliflozin124$138,209
EliquisApixaban145$132,408
MounjaroTirzepatide91$99,268
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$53,717
JanuviaSitagliptin Phosphate62$48,780
LinzessLinaclotide54$48,197
FarxigaDapagliflozin Propanediol57$48,126
XareltoRivaroxaban34$34,536
Tresiba Flextouch U-200Insulin Degludec35$32,240
JanumetSitagliptin Phos/Metformin Hcl23$30,541
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$30,380
Tresiba Flextouch U-100Insulin Degludec32$26,503
RybelsusSemaglutide19$20,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$359$238,448213 claims
Novo NordiskOzempic, Rybelsus, Novolog$199$177,513195 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$51$160,112149 claims
PfizerEliquis$78$132,408145 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$126$100,410148 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Arexvy$195$97,057216 claims
MerckJanuvia, Janumet$84$79,32185 claims
AbbVieLinzess, Vraylar, Synthroid$332$68,912114 claims
Johnson & JohnsonXarelto$27$34,53634 claims
NovartisEntresto$25$15,49416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Monticello

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →